Should therapy for hematologic malignancies be modified to mitigate poor COVID-19 outcomes?
Healio.com,
February 25, 2021 5 min read Source/Disclosures Published by: Disclosures: Bhutani reports no relevant disclosures.
February 25, 2021 5 min read Source/Disclosures Published by: Disclosures: Bhutani reports no relevant disclosures.
..Redacción. La infección por Covid-19 en pacientes con tumores hematológicos conlleva factores de riesgo de morbimortalidad.